Ionis Pharmaceuticals (IONS) Enterprise Value (2009 - 2026)

Ionis Pharmaceuticals' Enterprise Value history runs 18 years deep, the most recent figure standing at -$1.9 billion for Q1 2026.

• In Q1 2026, Enterprise Value rose 10.54% year-over-year to -$1.9 billion; the TTM figure through Mar 2026 stood at -$1.9 billion (up 10.54% YoY), while the FY2025 annual figure was -$2.7 billion, down 16.53% from the prior year.
• Enterprise Value was -$1.9 billion for Q1 2026 at Ionis Pharmaceuticals, up from -$2.7 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$1.9 billion in Q1 2026 to a low of -$2.7 billion in Q4 2025.
• Historically, Enterprise Value has averaged -$2.2 billion across 5 years, with a median of -$2.2 billion in 2023.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value fell 17.98% in 2023, then climbed 12.86% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$2.0 billion in 2022, then slipped by 17.33% to -$2.3 billion in 2023, then advanced by 1.44% to -$2.3 billion in 2024, then fell by 16.53% to -$2.7 billion in 2025, then increased by 28.32% to -$1.9 billion in 2026.
• The last three Enterprise Value figures came in at -$1.9 billion (Q1 2026), -$2.7 billion (Q4 2025), and -$2.2 billion (Q3 2025), per Business Quant data.